| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $105K | -75.4% |
| SG&A Expense | $1.1M | -53.1% |
| Net Income | -$6.2M | -45.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.0M | +19.8% |
| Accounts Receivable | $5K | -85.4% |
| Current Assets | $6.1M | +23.0% |
| Total Assets | $9.0M | +73.3% |
| Current Liabilities | $1.8M | +38.7% |
| Total Liabilities | $2.3M | +71.2% |
| Stockholders' Equity | $6.7M | +74.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$5.5M | -20.4% |
| Capital Expenditures | $9K | -18.1% |
| Investing Cash Flow | -$611K | -5355.8% |
| Financing Cash Flow | $6.8M | +0.3% |
| Free Cash Flow | -$5.5M | -20.3% |